Sterilization & Disinfection Control was Mesa Laboratories’s largest segment in fiscal 2026, bringing in $101.57M of $249.13M (41%).
| Segment | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sterilization & Disinfection Control | $64.61M | $75.12M | $93.42M | $101.57M | ||||||||||||
| Calibration Solutions | $44.81M | $47.76M | $51.75M | $53.55M | ||||||||||||
| Clinical Genomics | $62.30M | $52.59M | $47.08M | $45.39M | ||||||||||||
| Biopharmaceutical Development | $47.37M | $40.71M | $48.73M | $48.63M | ||||||||||||
| Sterilzation & Disinfection Control | — | — | — | — | ||||||||||||
| Instruments | — | — | — | — | ||||||||||||
| Biological Indicators | — | — | — | — | ||||||||||||
| Revenues | — | — | — | — | ||||||||||||
| Cold Chain Monitoring | — | — | — | — | ||||||||||||
| Continuous Monitoring | — | — | — | — | ||||||||||||
| Cold Chain Packaging | — | — | — | — | ||||||||||||
| Segment Reporting, Reconciling Item, Corporate Nonsegment | — | — | — | — | ||||||||||||
| Corporate, Non-Segment | — | — | — | — | ||||||||||||
| Total | $219.08M | $216.19M | $240.98M | $249.13M |
Mesa Laboratories brought in $249.13M from its four segments in fiscal 2026, the year ended March 31, 2026. That was up 3.4% from $240.98M in fiscal 2025. Sterilization & Disinfection Control was the largest at $101.57M (40.8%), ahead of Calibration Solutions at $53.55M (21.5%) and Biopharmaceutical Development at $48.63M (19.5%). The remaining segment, Clinical Genomics, brought in $45.39M.
Compared with fiscal 2025, Sterilization & Disinfection Control grew fastest, up 8.7% to $101.57M, while Clinical Genomics fell the most, down 3.6% to $45.39M. From fiscal 2023 to 2026, combined revenue from these segments grew from $219.08M to $249.13M, a compound annual growth rate of 4.4%. Sterilization & Disinfection Control's share of the total rose from 29.5% to 40.8%.
United States was Mesa Laboratories’s largest region in fiscal 2026, bringing in $116.90M of $249.13M (47%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | $76.00M | $84.86M | $99.05M | $111.79M | |||||||||||
| United States | $117.28M | $106.40M | $116.62M | $116.90M | |||||||||||
| Non-Us | — | — | — | — | |||||||||||
| Foreign | — | — | — | — | |||||||||||
| China | $25.80M | $24.93M | $25.31M | $20.45M | |||||||||||
| Total | $219.08M | $216.19M | $240.98M | $249.13M |
Mesa Laboratories brought in $249.13M from its three regions in fiscal 2026, the year ended March 31, 2026. That was up 3.4% from $240.98M in fiscal 2025. United States was the largest at $116.90M (46.9%), ahead of Other at $111.79M (44.9%) and China at $20.45M (8.2%).
Compared with fiscal 2025, Other grew fastest, up 12.9% to $111.79M, while China fell the most, down 19.2% to $20.45M. From fiscal 2023 to 2026, combined revenue from these regions grew from $219.08M to $249.13M, a compound annual growth rate of 4.4%. United States' share of the total fell from 53.5% to 46.9%.
Consumables was Mesa Laboratories’s largest product and service line in fiscal 2026, bringing in $145.94M of $249.13M (59%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $117.84M | $120.98M | $138.73M | $145.94M | |||||||
| Product | — | — | — | — | |||||||
| Hardware & Software | $62.68M | $55.82M | $59.66M | $57.45M | |||||||
| Service | $38.56M | $39.39M | $42.58M | $45.74M | |||||||
| Total | $219.08M | $216.19M | $240.98M | $249.13M |
Mesa Laboratories brought in $249.13M from its three product and service lines in fiscal 2026, the year ended March 31, 2026. That was up 3.4% from $240.98M in fiscal 2025. Consumables was the largest at $145.94M (58.6%), ahead of Hardware & Software at $57.45M (23.1%) and Service at $45.74M (18.4%).
Compared with fiscal 2025, Service grew fastest, up 7.4% to $45.74M, while Hardware & Software fell the most, down 3.7% to $57.45M. From fiscal 2023 to 2026, combined revenue from these lines grew from $219.08M to $249.13M, a compound annual growth rate of 4.4%. Consumables' share of the total rose from 53.8% to 58.6%.
Mesa Laboratories (MLAB) reports its revenue by segment, by geography and by product and service. In fiscal 2026, Sterilization & Disinfection Control was its largest segment, bringing in $101.57M (40.8% of the total), followed by Calibration Solutions at $53.55M (21.5%).
Sterilization & Disinfection Control was Mesa Laboratories' largest segment in fiscal 2026, bringing in $101.57M, or 40.8% of the $249.13M total across its four segments.
United States was Mesa Laboratories' largest region in fiscal 2026, bringing in $116.90M, or 46.9% of the $249.13M total across its three regions.
Consumables was Mesa Laboratories' largest product and service line in fiscal 2026, bringing in $145.94M, or 58.6% of the $249.13M total across its three product and service lines.
Among Mesa Laboratories' segments that make up at least 2% of revenue, Sterilization & Disinfection Control grew fastest in fiscal 2026, up 8.7% from $93.42M to $101.57M.
Every figure comes from Mesa Laboratories' annual financial filings, as reported. Each line keeps the name Mesa Laboratories gives it, and years follow its fiscal calendar.
Mesa Laboratories' revenue by segment goes back to fiscal 2011, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.